Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Metastatic Prostate Cancer (Dec 2020)

Posted by Matt Breese on Jan 1, 2021

Find me on:

According to our recent payer coverage analysis for metastatic prostate cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for metastatic prostate cancer treatments shows that under the pharmacy benefit, almost 56% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Metastatic Prostate Cancer-4Q2020Data snapshot as of Q4 2020

Trends: Although poly (ADP-ribose) polymerase (PARP) inhibitors are not new to the market, two of them — AstraZeneca and Merck & Co., Inc.’s Lynparza (olaparib) and Clovis Oncology, Inc.’s Rubraca (rucaparib) — gained approval for use in prostate cancer for the first time in 2020. The therapies will bring a new option for the treatment of certain subpopulations of patients.  

To read the full Reality Check on Metastatic Prostate Cancer treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing